Apparent cyclophosphamide (Cytoxan) embryopathy: A distinct phenotype?

American Journal of Medical Genetics

Volumn 86, Issue 3, 1999, Pages 237-241

  Enns, Gregory M ^a   Roeder, Elizabeth ^b   Chan, Ruth T ^c   Catts, Zohra Ali Khan ^b   Cox, Victoria A ^a   Golabi, Mahin ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclophosphamide; Cytoxan; Malformation; Teratogenesis

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CLONIDINE; CYCLOPHOSPHAMIDE; NIFEDIPINE; PREDNISONE;

ADULT; ARTICLE; BLEPHAROPHIMOSIS; BRACHYCEPHALY; CASE REPORT; CRANIOFACIAL SYNOSTOSIS; EAR MALFORMATION; EMBRYOPATHY; EXOPHTHALMOS; FEMALE; GROWTH RETARDATION; HUMAN; HYPOTELORISM; INFANT; MICROGNATHIA; MICROSTOMIA; PHENOTYPE; POLYDACTYLY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ABNORMALITIES, MULTIPLE; ADULT; ANIMALS; BLEPHAROPHIMOSIS; CRANIOSYNOSTOSES; CYCLOPHOSPHAMIDE; DEVELOPMENTAL DISABILITIES; EAR, EXTERNAL; FEMALE; GROWTH DISORDERS; HUMANS; INFANT, NEWBORN; LIMB DEFORMITIES, CONGENITAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MATERNAL-FETAL EXCHANGE; PHENOTYPE; PREGNANCY; PREGNANCY COMPLICATIONS; TERATOGENS;

ANIMALIA;

EID: 0032847866     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V     Document Type: Article

References (32)

1. Ashby R, Davis L, Dewhurst BB, Espinal R, Penn RN, Upshall DG. 1976. Aspects of the teratology of cyclophosphamide (NSC-26271). Cancer Treat Rep 60:477-482.
2. Bermas BL, Hill JA. 1995. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 38:1722-1732.
3. Briggs GG, Freeman RK, Yaffe SJ. 1994. "A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation." Baltimore: Williams & Wilkins.
4. Chaube S, Kury G, Murphy ML. 1967. Teratogenic effects of cyclophosphamide (NSC-26271) in the rat. Cancer Chemother Rep 51:363-376.
5. Coates A. 1970. Cyclophosphamide in pregnancy. Aust NZJ Obstet Gynaec 10:33-34.
6. D'Incalci M, Sessa C, Columbo N, de Palo G, Semprini AE, Pardi G. 1982. Transplacental passage of cyclophosphamide. Cancer Treat Rep 66: 1681-1682.
7. Francis BM, Rogers JM, Sulik KK, Alles AJ, Elstein KH, Zucker RM, Massaro EJ, Rosen MB, Chernoff N. 1990. Cyclophosphamide teratogenesis: evidence for compensatory responses to induced cellular toxicity. Teratol 42:473-482.
8. Fritz H, Hess R. 1971. Effects of cyclophosphamide on embryonic development in the rabbit. Agents Action 2:83-86.
9. Gebhardt DOE. 1970. The embryolethal and teratogenic effects of cyclophosphamide on mouse embryos. Teratol 3:273-278.
10. Gibson JE, Becker BA. 1968. The teratogenicity of cyclophosphamide in mice. Cancer Res 28:475-480.
11. Gilani SH, Chatzinoff M. 1983. Embryopathic effects of cyclophosphamide. Environ Res 31:296-301.
12. Greenberg LH, Tanaka KR. 1964. Congenital anomalies probably induced by cyclophosphamide. JAMA 188:423-426.
13. 2 progeny of male rats chronically treated with cyclophosphamide. Teratol 45:671-678.
14. Jeyaseelan N, Singh S. 1984. Forelimb malformation in rats caused by cyclophosphamide. Acta Orthop Scand 55:643-646.
15. Kirshon B, Wasserstrum N, Willis R, Herman GE, McCabe ERB. 1988. Teratogenic effects of 1st-trimester cyclophosphamide therapy. Obstet Gynecol 72:462-464.
16. Manson JM, Smith CC. 1977. Influence of cyclophosphamide and 4-ketocyclophosphamide on mouse limb development. Teratol 15:291-300.
17. Manson JM, Papa L, Miller ML, Boyd C. 1982. Studies of DNA damage and cell death in embryonic limb buds induced by teratogenic exposure to cyclophosphamide. Terat Carcinogen Mutagen 2:47-59.
18. McClure HM, Wilk AL, Horigan EA, Pratt RM. 1979. Induction of craniofacial malformations in Rhesus monkeys (Macaco mulatto) with cyclo-phosphamide. Cleft Pal J 16:248-256.
19. Mirkes PE. 1985. Cyclophosphamide teratogenesis: a review. Terat Carcin Mutagen 5:75-88.
20. Moore KL. 1982. "The Developing Human: Clinically Oriented Embryology." Philadelphia: W.B. Saunders, p 85-89.
21. Murray CL, Reichert JA, Anderson J, Twiggs LB. 1984. Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. JAMA 252:2607-2608.
22. Mutchinick O, Aizpuru E, Grether P. 1992. The human teratogenic effect of cyclophosphamide. Aust Terat Abs 45:329.
23. Nguyen Tan Lung R, Cranier M, Gaudry C, Kourilsky O. 1995. Cyclophosphamide en cours de grossesse: une prescription acceptable. J Gyn Obstet Biol Reprod 24:314-318.
24. Nicholson HO. 1968. Cytotoxic drugs in pregnancy: review of reported cases. J Obstet Gynaec Brit Cwlth 75:307-312.
25. Padmanabhan R, Singh S. 1984. Congenital anomalies of the ear resulting from cyclophosphamide treatment in the rat. Acta Anat 119:217-223.
26. Pizzuto J, Aviles A, Noriega L, Niz J, Morales M, Romero F. 1980. Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep 64:679-683.
27. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger TA. 1993. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppresive drugs. J Rheumatol 20:1152-1157.
28. Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, Doney K, Storb R, Sullivan K, Witherspoon R, Appelbaum FR. 1996. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 87:3045-3052.
29. Singh S. 1971. The teratogenicity of cyclophosphamide (endoxan-asta) in rats. Indian J Med Res 59:1128-1135.
30. Sweet DL, Kinzie J. 1976. Consequences of radiotherapy and antineoplastic therapy for the fetus. J Reprod Med 17:241-246.
31. Toledo TM, Harper RC, Moser RH. 1971. Fetal effects during cyclophosphamide and irradiation therapy. Ann Intern Med 74:87-91.
32. Zemlickis D, Lishner M, Erlich R, Koren G. 1993. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Terat Carcin Mutagen 13:139-143.